Uptake and utilization of directly acting antiviral medications for hepatitis C infection in US veterans

被引:6
作者
Gidwani, R. [1 ,2 ,3 ,4 ]
Barnett, P. G. [1 ,5 ]
Goldhaber-Fiebert, J. D. [3 ,4 ]
Asch, S. M. [2 ,3 ]
Lo, J. [1 ]
Dally, S. K. [1 ]
Owens, D. K. [2 ,3 ,4 ]
机构
[1] VA Hlth Econ Resource Ctr, Menlo Pk, CA 94025 USA
[2] VA Ctr Innovat Implementat, Menlo Pk, CA USA
[3] Stanford Univ, Dept Med, Stanford, CA 94305 USA
[4] Stanford Univ, Ctr Primary Care & Outcomes Res, Ctr Hlth Policy, Stanford, CA 94305 USA
[5] Stanford Univ, Dept Hlth Res & Policy, Stanford, CA 94305 USA
关键词
boceprevir; IL-28B; Interferon; ribavirin; telaprevir; PLUS RIBAVIRIN; PEGINTERFERON ALPHA-2A; VIRUS-INFECTION; SOFOSBUVIR;
D O I
10.1111/jvh.12344
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
New drugs therapies have revolutionized the treatment of hepatitis C virus (HCV) infection. The objectives of this study were to evaluate uptake and utilization of boceprevir and telaprevir in the Department of Veterans Affairs (VA). We evaluated whether therapies conformed to response-guided protocols, whether they replaced standard interferon plus ribavirin treatment, and whether IL-28B was used to guide treatment. We performed an administrative data-based analysis of all patients receiving pharmacologic treatment for HCV in VA from October 2009 to July 2013. There were 12737 new HCV prescriptions in VA during this time, with 5564 boceprevir or telaprevir prescriptions (44%) and 7173 prescriptions (56%) written for standard interferon plus ribavirin treatment. Prescriptions for the new treatments heavily favoured boceprevir vs telaprevir (83% vs 17%). Sixty-two percent (62%) of boceprevir-treated patients completed their minimum-specified protocol, while 69.2% of telaprevir-treated patients completed their minimum-specified protocol. From October 2010 to July 2012, 4090 patients had an IL-28B test; less than 16% of these tests guided subsequent HCV prescriptions. Uptake of boceprevir and telaprevir was rapid; the number of patients initiating treatment approximately doubled in the period after their introduction. While new prescriptions favor boceprevir or telaprevir over standard interferon plus ribavirin therapy, there appears to still be a strong role of interferon plus ribavirin in treating HCV patients. This work can inform our understanding of how other new effective HCV therapies will be used, their diffusion, and the timing of their diffusion in actual clinical practice.
引用
收藏
页码:489 / 495
页数:7
相关论文
共 50 条
  • [41] Cascade of Care for Hepatitis C Virus Infection Within the US Veterans Health Administration
    Maier, Marissa M.
    Ross, David B.
    Chartier, Maggie
    Belperio, Pamela S.
    Backus, Lisa I.
    AMERICAN JOURNAL OF PUBLIC HEALTH, 2016, 106 (02) : 353 - 358
  • [42] Hepatitis C virus infection in children in the era of direct-acting antiviral
    Pawlowska, Malgorzata
    Sobolewska-Pilarczyk, Malgorzata
    Domagalski, Krzysztof
    WORLD JOURNAL OF GASTROENTEROLOGY, 2018, 24 (24) : 2555 - 2566
  • [43] COLOMBIAN EXPERIENCE IN THE TREATMENT OF HEPATITIS C WITH DIRECT-ACTING ANTIVIRAL AGENTS
    Varon, Adriana
    Santos, Luisa
    Tapias, Monica
    Caez, Clara
    Ignacio Marin, Juan
    Santos, Oscar
    Garzon, Martin
    Beltran, Oscar
    Gomez-Aldana, Andres
    Yepes, Ismael J.
    Rondon, Martin
    Rosselli, Diego
    MEDICINA-BUENOS AIRES, 2019, 79 (01) : 29 - 36
  • [44] Effect of immunogenetics polymorphism and expression on direct-acting antiviral drug response in chronic hepatitis C
    Abdelaziz, Aya Ismail
    Abdelsameea, Eman
    Abdel-Samiee, Mohamed
    Ghanem, Samar E.
    Wahdan, Sara A.
    Elsherbiny, Doaa A.
    Zakaria, Zeinab
    Azab, Samar S.
    CLINICAL AND EXPERIMENTAL MEDICINE, 2024, 24 (01)
  • [45] Hepatitis C late relapse in patients with directly acting antiviral-related sustained virological response at week 12
    Pisaturo, Mariantonietta
    Minichini, Carmine
    Starace, Mario
    Caroprese, Mara
    Macera, Margherita
    Brancaccio, Giuseppina
    De Pascalis, Stefania
    Santonicola, Antonella
    Lanza, Alfonso Galeota
    Zampino, Rosa
    Cotticelli, Gaetano
    Sagnelli, Evangelista
    Gaeta, Giovanni Battista
    Coppola, Nicola
    LIVER INTERNATIONAL, 2019, 39 (05) : 844 - 853
  • [46] Hepatitis C infection, antiviral treatment and mental health: A European expert consensus statement
    Schaefer, Martin
    Capuron, Lucile
    Friebe, Astrid
    Diez-Quevedo, Crisanto
    Robaeys, Geert
    Neri, Sergio
    Foster, Graham R.
    Kautz, Achim
    Forton, Daniel
    Pariante, Carmine M.
    JOURNAL OF HEPATOLOGY, 2012, 57 (06) : 1379 - 1390
  • [47] Direct-acting antiviral retreatment patterns for hepatitis C
    Al Hasan, Shaquib
    Dauner, Daniel G.
    Rajpurohit, Abhijeet
    Farley, Joel F.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2022, 28 (10) : 1100 - 1110
  • [48] Disparities in Initiation of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection in an Insured Population
    Marcus, Julia L.
    Hurley, Leo B.
    Chamberland, Scott
    Champsi, Jamila H.
    Gittleman, Laura C.
    Korn, Daniel G.
    Lai, Jennifer B.
    Lam, Jennifer O.
    Pauly, Mary Pat
    Quesenberry, Charles P.
    Ready, Joanna
    Saxena, Varun
    Seo, Suk I.
    Witt, David J.
    Silverberg, Michael J.
    PUBLIC HEALTH REPORTS, 2018, 133 (04) : 452 - 460
  • [49] Interferon-α/β for treatment of chronic hepatitis C infection in the era of direct-acting antiviral agents
    Enomoto, Masaru
    Tamori, Akihiro
    Murakami, Yoshiki
    Kawada, Norifumi
    HEPATOLOGY RESEARCH, 2014, 44 (04) : 371 - 376
  • [50] Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 US Veterans
    Backus, L. I.
    Belperio, P. S.
    Shahoumian, T. A.
    Loomis, T. P.
    Mole, L. A.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (05) : 559 - 573